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Abstract
Introduction: Research is an essential tool in facing the challenges of scaling up interventions and
improving access to services. As in many other countries, the translation of research evidence into
drug policy action in Tanzania is often constrained by poor communication between researchers
and policy decision-makers, individual perceptions or attitudes towards the drug and hesitation by
some policy decision-makers to approve change when they anticipate possible undesirable
repercussions should the policy change as proposed. Internationally, literature on the role of
researchers on national antimalarial drug policy change is limited.
Objectives: To describe the (a) role of researchers in producing evidence that influenced the
Tanzanian government replace chloroquine (CQ) with sulfadoxine-pyrimethamine (SP) as the first-
line drug and the challenges faced in convincing policy-makers, general practitioners,
pharmaceutical industry and the general public on the need for change (b) challenges ahead before
a new drug combination treatment policy is introduced in Tanzania.
Methods: In-depth interviews were held with national-level policy-makers, malaria control
programme managers, pharmaceutical officers, general medical practitioners, medical research
library and publications officers, university academicians, heads of medical research institutions and
district and regional medical officers. Additional data were obtained through a review of malaria
drug policy documents and participant observations were also done.
Results: In year 2001, the Tanzanian Government officially changed its malaria treatment policy
guidelines whereby CQ – the first-line drug for a long time was replaced with SP. This policy
decision was supported by research evidence indicating parasite resistance to CQ and clinical CQ
treatment failure rates to have reached intolerable levels as compared to SP and amodiaquine
(AQ). Research also indicated that since SP was also facing rising resistance trend, the need for a
more effective drug was indispensable but for an interim 5–10 year period it was justifiable to
recommend SP that was relatively more cost-effective than CQ and AQ. The government launched
the policy change considering that studies (ethically approved by the Ministry of Health) on
therapeutic efficacy and cost-effectiveness of artemisinin drug combination therapies were
underway. Nevertheless, the process of communicating research results and recommendations to
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Malaria Journal 2005, 4:51 http://www.malariajournal.com/content/4/1/51policy-making authorities involved critical debates between policy makers and researchers, among
the researchers themselves and between the researchers and general practitioners, the speculative
media reports on SP side-effects and reservations by the general public concerning the rationale
for policy change, when to change, and to which drug of choice.
Conclusion: Changing national drug policy will remain a sensitive issue that cannot be done
overnight. However, to ensure that research findings are recognised and the recommendations
emanating from such findings are effectively utilized, a systematic involvement of all the key
stakeholders (including policy-makers, drug manufacturers, media, practitioners and the general
public) at all stages of research is crucial. It also matters how and when research information is
communicated to the stakeholders. Professional organizations such as the East African Network
on Malaria Treatment have potential to bring together malaria researchers, policy-makers and
other stakeholders in the research-to-drug policy change interface.
Introduction
Malaria is still the leading cause of morbidity and mortal-
ity in sub-Saharan Africa especially in young children and
pregnant women [1]. Considering the limited health
budgets and the rising cost of medical services, the
increasing trends of drug resistance raise critical public
health concerns, as this constrains the provision of ade-
quate treatment in countries where the disease is endemic.
The increasing evidence on Plasmodium falciparum parasite
resistance to chloroquine (CQ) has prompted some coun-
tries to revise their treatment guidelines [2]. In the last
decade, the immediately considered alternative first-line
drug in some southern African countries, such as South
Africa, Botswana, Malawi and Kenya, was SP, but now,
countries such as Burundi and Rwanda have already opted
for artemisinin drug combination therapy while several
others are considering to do so [3]. In many countries, the
hesitation by ministries of health to make a policy change
decision has been over-influenced by economic budget
considerations [4,5]. In Tanzania, the critical nature of the
decision to switch to a new first-line drug was closely
linked with the estimated budget for the policy change of
US $100.8 million [6], which represented 3.4% of the
GNP.
Located between latitudes 1°S and 12°S and longitudes
30°E and 40°E, the United Republic of Tanzania covers
an area of 945,050 km2, including 59,050 km2 of inland
waters [7]. Malaria has been the most life-threatening
public disease in terms of morbidity and mortality in Tan-
zania since the colonial era, and today has a critical influ-
ence on the poverty cycle. One recent study showed that
malaria reduces the national economic growth by 1.3%
[8]. The same study revealed that contributing to about
40,000 deaths annually malaria puts nearly 35 million
Tanzanian population at risk. Furthermore, records show
malaria accounting to a third of all outpatient visits, a
third of inpatient admissions and a third of deaths among
children under the age of five years admitted to hospitals
[9,10]. Also the national annual health-facility-based sta-
tistics for the last ten years (1995–2004) indicate malaria
as the highest cause of outpatient attendance in people
aged 5 years and above and deaths in hospitalized
patients of all age groups.
In Tanzania, the capacity to respond to this malaria prob-
lem and other health crises is highly constrained by the
meagre Government spending of US $4 per capita on
health, with a range of 8–10% of total government budget
[11]. The large external debt exerts pressure on the Gov-
ernment's limited resources and in its struggle to eradicate
poverty. Tanzania is one of the poorest countries with a
per capita income of US $170 per year, about 27% of the
population spending less than $0.50 per day on overall
needs, 48% spending less than $0.65 per day on basic
needs while the real annual economic growth-rate was
about 4.9% by year 1999 [12].
For the last 45 years or so, CQ has been the first line drug
in nearly all malaria endemic SSA countries. This is due to
its ready availability in kiosks, shops and drug stores, as
well as from formal health facilities, its relatively low cost
per dose and its safety [13]. Until the last day of July 2001,
CQ was officially the first-line drug for the treatment of
uncomplicated malaria in Tanzania, SP being the second-
line drug while quinine was the third-line drug for severe
or complicated malaria [14]. As in many other tropical
countries, the treatment of malaria has ranged from self-
medication using traditional medicines to the use of mod-
ern pharmaceuticals [15]. In the context of high levels of
poverty, exacerbated by diseases and external pressures, it
is initially difficult to implement large-scale and sustaina-
ble policy changes even if there is available evidence to
support them. This has been the case with recent changes
in the malaria treatment policy in Tanzania.
Conceptual framework
The paper is part of a series of case-studies undertaken by
the Alliance for Health Policy and Systems Research
(AHPSR) to identify the production and utilization ofPage 2 of 13
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tries. An attempt has been made to describe an enabling
environment for the demand for research evidence and its
utilization, including research funding, research priority
setting, institutional support and commissioning. Case-
studies were prepared to encourage discussion about the
processes and mechanisms which affect support for
research and its impact and identification of the chal-
lenges in setting research priorities, decision-makers' sup-
port for research and the benefits gained from the research
process and its results.
In the Tanzanian case-study, particular attention was paid
to describing the role of diverse mechanisms and actors in
the research-to-policy change process. The impact of
HPSR was analysed by observing research inputs and deci-
sion outputs in specific policy development situations
[16]. Research inputs would be studied from the supply
side by analysing problems of HPSR dissemination, and
from the demand side through an examination of the par-
ticipation of researchers as part of the policy-making proc-
ess. The influence of different types of knowledge – from
empirical findings in data-driven design situations to
broad conceptual policy frameworks was explored.
Research is greatly under-utilized as a tool to guide health
policy formulation, improvement and practice, particu-
larly in the challenges of scaling up interventions and
improving access to services in developing health systems.
There is a general lack of formal interfaces and linkage
strategies to ensure that research supports policy develop-
ment. To improve utilization, it is important to reveal the
policy framework through which researchers can or have
influenced decisions. This involves looking at how policy-
makers and service managers can use or have effectively
used the available research information and how
researchers can be or have been promoted to interact
among themselves and other key stakeholders in the pol-
icy arena [16]. In Tanzania and East Africa, a number of
policy initiatives and research projects have supported
research undertakings, evidence production and utiliza-
tion. The Tanzania National Health Research Forum
(TANHERF) has been the prime priority-setting mecha-
nism since 1999 and has led to the establishment of an
institutional framework for mediating the communica-
tion of research evidence to policy-makers [17]. The NIMR
and TEHIP have functioned as secretariat for the Forum
[18,19] (see Figures 1 &2).
In this paper, a description is given on the process of
changing the malaria treatment policy by replacing CQ
with SP as the first-line antimalarial drug in Tanzania.
Focus is on the process and role of researchers in provid-
ing evidence to and their interaction with policy-makers
and other stakeholders and the challenges ahead before a
government decision to switch from SP to artemisinin
drug combination therapy.
Study Methods
Scope of the study and study design
The case study was exploratory in design, undertaken
between June, 2001 and November, 2002 to assess the
value of existing institutional mechanisms and interfaces
in Tanzania with reference to a recent national antimalar-
ial drug policy change. Focus has been on the role of, and
methods used by researchers and research institutions in
producing and communicating evidence on antimalarial
drug resistance situation and cost-effectiveness of alterna-
tive drugs to policy-makers and other stakeholders (med-
ical practitioners, local pharmaceutical manufacturers,
traders and community representatives). The study was
built on the conception that research is greatly under-uti-
lized as a tool to guide the health policy-making process,
policy improvement and practice, considering the emerg-
ing challenges to scaling up interventions and improving
access to services in developing health systems of coun-
tries such as Tanzania. Also considering that policy-mak-
ing is greatly influenced by health professionals, industry
and to some extent the public [16] it was imperative to
analyse the relationship between research undertakings to
produce evidence for explicit policy decision and the
actual utilization of evidence by policy decision-makers.
Sampling
The target was to approach people who played one or sev-
eral of the following roles or by virtue of their designa-
tions: research experience on malaria drugs for at least 5
years, members of various committees involved in discus-
sions on drug policy issues at national level, general prac-
titioners, and lecturers in health policy aspects at high
learning institutions. In total, 21 officers were inter-
viewed, including 10 senior malaria researchers, two pol-
icy-makers, one officer working with the national
pharmacy board, four national-level malaria programme
managers, five general medical practitioners (of who one
was district- and one a regional medical officer), two uni-
versity teaching hospital lecturers, two medical research
publications and documentations officers, two heads of
medical research institutions. Of all the respondents,
eight were medical doctors with long experience in
malaria case management.
Major themes covered in the indepth interviews and 
document review
Generally interviewees were asked for their opinions
about (i) initiatives that were available to produce
research evidence to inform national policy-makers about
the efficacy and effectiveness of different antimalarial
drugs, the actors involved in such research initiatives and
the financial, institutional and political environment toPage 3 of 13
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Actors in the research-to-policy interaction process in Tanzania.
MoH/Minister for Health
Permanent Secretary of the MoH
Chief Medical Officer of MoH
Directorate of
Hospital Services
Directorate of Preventive Services Directorate of Planning & Policy
Intermediate Institutions/Organizations
e.g. NIMR & Others
NIMRTANHERF NMCP Bi- & Multi-lateral
Agencies e.g. WHO
Other Institutions with NIMR as their prefect
- Ifakara Centre
- University Teaching Hospitals (KCMC,
MUCHS, St Augustine-Bugando, Hubert
Kairuki Memorial)
- Private Sector Agencies (pharmaceutical
industry)
- National Pharmacy Board
- Office of the Chief Government Chemist
- Regional and District Health Authorities
- Religious Institutions and other-
- Community Representatives
- Professional Associations (e.g. Medical
Associations of Tanzania (MAT) and
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Time-line of key events in the Research-to-Policy process (summary).
Figure 2.
1970: Accumulating evidence during
the ‘alert period’ that CQ resistance
was beginning to appear. The main
evidence being the clinical
observation that gradually increasing
dosage of CQ were needed to obtain
a clinical effect
Time Line of Key Events in the “Research to Policy” Process [Summary]
1997: Zul Premji’s Study on CQ treatment
failure presented at the 1997 NIMR Annual
Joint Scientific Conference in Arusha, but
critically queried by the senior Officers 
from MoH Headquarters
1997: EANMAT created and
the selection of sentinel sites
for monitoring drug resistance 
d
1999: Task Force on Anti-malarial
Drug Policy created to report to the
National Malaria Advisory
Committee, within the National
Malaria Control Programme-NMCP
1999 (May): Bagamoyo
Workshop, in collaboration with
the WHO Roll Back Malaria
(RBM) programme
1999 (July): Task Force
submits 5-page policy brief to
the Ministry of Health, dated
23rd July 1999
2000 (February): Abdulla report
on cost-effectiveness analysis of
antimalarial drugs submitted to the
MoH/NMCP and WHO
2000 (June): Minister of Health
presents an agenda emphasizing the
alarming situation of CQ resistance
and treatment failures, malaria
related morbidity and mortality and
the need for an effective treatment2001: During the MoH’s
Parliamentary Budget Session,
the Government approves SP
as the first line and the whole
proposal for the new treatment
guidelines
1st August 2001: The policy becomes effectively
implemented in the national health system system
1986: Mutabingwa et al
publishing research paper about
CQ resistance in Muheza district,
TanzaniaPage 5 of 13
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looked at what prompted researchers develop interest in
antimalarial drug studies (including how the research
topic was identified and priorities set), and how were the
studies funded and how were the reports from such stud-
ies communicated to policy-makers and other potential
stakeholders (ii) research reports showing that due to
increasing trend in parasite resistance to CQ and its treat-
ment failures compared to other antimalarial drugs the
government urgently needed to revise its malaria treat-
ment guidelines (iii) as potential research-to-policy
actors, experiences they have had seeing research evidence
utilised by national antimalarial drug policy-makers. This
component observed the mechanisms involved in bring-
ing together researchers and policy-makers to policy dis-
cussion tables on aspects related to malaria treatment
using various antimalarial drugs and the challenges faced
so far and those ahead. The document review comple-
mented the interviews by observing the local and interna-
tional institutions involved in the antimalarial research-
to-policy interplay since independence, the funding of the
research, the output from several studies commissioned
by the government, the WHO and bilateral and multilat-
eral organisations supporting health research and
development.
Data collection methods
In 2001, WHO Geneva through technical experts of the
Alliance for Health Policy and Systems Research (AHPSR),
an initiative of the WHO and the GFHR provided a stand-
ard study framework highlighting key themes to be cov-
ered by all the case studied supported by the AHPSR. The
framework was validated for its applicability in the con-
text of the country and topic of the case study in question.
It also provided guidance for the analysis of the study
results. Based on such a framework, research instruments
were designed to allow the collection of information
through (i) a review of official reports and other docu-
ments (ii) in-depth interviews with malaria researchers,
policy-makers, programme managers and health workers
and at institutional and national levels and the national
pharmacy board officers (iii) participant observation (the
listed first author in this paper participated in the study in
the costs, effects and cost-effectiveness of changing the
first-line antimalarial drug policy in Tanzania, a study
which was commissioned by the NMCP and undertaken
by researchers from four research institutions as identified
later. Additional information was obtained from district
and regional medical officers' meetings, participation in
health research and policy conferences held in the country
as organized by NIMR, TMA, TPHA and the Multilateral
Initiative on Malaria.
Data handing and analysis
Most of the respondents suggested to be confronted as
many times as it would be found necessary for additional
information or clarity needed, so did not see the need for
being tape-recorded. Therefore, interviews were recorded
through hand written notes and the interviewer was keen
in noting down all the important explanations expressed
by the individual respondents. With reference to the study
themes/questions and as is recommended in case studies
[20], the analysis exercise looked at the content, context,
actors, process and pattern of the views expressed by dif-
ferent individual respondents. Attempt was made to note
the similarities and contrasts and the possible explana-
tions for the contrasting views.
Results
A summary of the content, patterns, context, actors and
processes involved in the research-to-policy process has
been presented in Table 2. The subsequent sections give a
more detailed account of the interface and interplay
between and among the actors involved in the process.
Formulation of the need for policy change
The period from mid 1980s marked an increasing interest
in antimalarial drug resistance among biomedical
researchers in Tanzania. Thus, several small-scale clinical
trials were conducted by researchers from the NIMR in
collaboration with local and foreign universities, funded
by bilateral agencies such as SDC, DANIDA, USAID, DFID
and multilateral agencies including WHO, UNDP and
UNICEF. Findings from each of such studies gave evi-
dence that CQ was increasingly facing resistance and treat-
ment failures.
Spread of drug resistance and recommended level to 
prompt policy change
The need for changing the policy came from accumulated
evidence and increasing debates on increasing trend of P.
falciparum resistance to CQ, that has been observed in
different parts of the country [21-26] since the mid-1950s
(also see Table 1 & Figure 1), through to 1970s [27] and
the last two decades [4,28]. The Minister of Health, Hon.
Anna Abdallah, informed the Parliament of the United
Republic of Tanzania during the 2002–2003 budgetary
session that her Ministry's decision to suspend CQ as the
first-line drug was based on sound evidence pointing to
the high cure-rate failure of about 60% while the SP cure
rate was 85–90% and was more cost-effective than other
antimalarials [27]. While WHO recommends policy
change to an alternative drug when the treatment failure
reached 25%, evidence from different sentinel sites in the
country indicated that up to the time of policy change, CQ
treatment failure rate [6] had already reached 52% (rang-
ing 28–72%), 9.5% for SP (ranging 6–32%), and other
drugs such as amodiaquine (AQ) and quinine was lessPage 6 of 13
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of malaria morbidity and mortality in the country, from
year to year, was associated by local and foreign research-
ers with the increasing trend of parasite resistance to CQ.
Concern was, therefore, raised about the need to review
and improve the national malaria treatment policy guide-
lines. Another important reason for the increased enthusi-
asm for policy change towards the end of 1990s is that
some countries such as Kenya, Botswana, Malawi and
South Africa had already revised their national drug policy
guidelines whereby SP had replaced CQ as the first-line
drug [6].
Actors in research to policy
WHO Geneva [through TDR]
Between April–May 1996, WHO through TDR organized
an inter-country workshop in Tanga Region, Tanzania
aimed at training biomedical researchers and discussing
the improved protocol for testing the therapeutic efficacy
of CQ, SP and other antimalarials. This workshop was
organized to support enhancement of research capacity in
collecting, documenting and reporting evidence on anti-
malarial drug resistance as a milestone for guiding
national drug policy review process.
EANMAT
Formed in 1997 and supported by DFID, DANIDA and
several other agencies, the East African Network on Mon-
itoring Antimalarial Treatment (EANMAT) was estab-
lished to bring malaria researchers and policy-makers
from Ministries of Health in the three East African coun-
tries, Kenya, Uganda and Tanzania although Rwanda
joined the Network later in 1999. EANMAT's mission is to
have a network that would enable the regular monitoring
of treatment outcome of the commonly used first and
second-line anti-malarial drugs, based on which rational
anti-malarial treatment policies would be developed.
EANMAT has a secretariat coordinating the activities of
member countries according to its constitution and has
generated important malaria treatment database that has
contributed to the review and modifications of malaria
treatment policies in member countries, whereby in Tan-
zania the data started to be effectively utilized at policy
dialogue level in May 1999. EANMAT also provided funds
for the second study phase on the efficacy of AQ, Lapdap
and other alternative anti-malarial drugs and produced a
standard malaria treatment protocol for East African
countries for consideration by countries [4].
Sentinel sites for antimalarial drug resistance monitoring
In 1997, the MoH of Tanzania through its NMCP, in col-
laboration with EANMAT, decided to select nine areas in
different parts of the country to act as sentinel sites for
monitoring antimalarial drug resistance. These sites were
selected on a number of criteria, including areas with dif-
ferent socio-economic characteristics and accessibility to
antimalarial drug sources and varying malaria endemicity
and drug resistance patterns. This was followed by the
NMCP with support from WHO and other donors to com-
mission a number of studies from research institutions
like NIMR and IHRDC, university teaching hospitals, and
other institutions to monitor drug resistance and report
findings to the Government for consideration. From their
inception, the sentinel sites have provided an environ-
ment for producing evidence based on which the National
Task Force on Antimalarial Drug Policy and EANMAT
developed a policy-brief summary to feedback to the
national policy makers, who were finally convinced of the
widespread CQ resistance and clinical treatment failures
throughout the country, which had never happened
previously.
The National Task Force on Antimalarial Drug Policy
The National Task Force on Antimalarial Drug Policy was
formulated in May 1999 as a sub-committee of the
National Malaria Advisory Committee (NMAC) in con-
sultation with the EANMAT and WHO country office in
Dar Es Salaam. This body is comprised of interdisciplinary
professionals, some of them from the MoH acting as key
policy decision-makers (including the Director of Preven-
tive Services, NIMR's Director General, Muhimbili
National Hospital, the National Pharmacy Board, Inte-
grated Management of Childhood Illnesses (IMCI) and
the Medical Stores Department). WHO Country office
Table 1: Trends in antimalarial drug resistance in Tanzania, 1950s–1990s
Period Resistance pattern to chloroquine up to 1999
Early 1950s A dose of 2.5 mg/kg is still efficacious (grace period)
Mid-1970s Owing to slow increase in resistance, the therapeutic dose was gradually increased to the maximum safe level of 25 mg/kg (alert 
period)
Late 1980s Resistance to the maximum dose began to reach levels of significant public health importance (alert period)
Mid-1990s WHO recommended drug policy action if resistance (total treatment failure) reaches 25% (change period)
Late 1990s Tanzania established sentinel sites in nine regions to monitor resistance by standard methods
Source: Ministry of Health, 1999.Page 7 of 13
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Force and the NMAC and in providing the necessary and
feasible technical and material assistance.
On 23rd July 1999, the Task Force developed a three-page
summary, drawing on evidence from clinical trials in the
sentinel sites. This information was supplemented with a
review of national health management information
(HMIS) records, as a research policy-brief to highlight to
national policy-makers the trend in antimalarial drug
resistance, the status of malaria-related morbidity and
mortality, and provide immediate suggestions for short
and long term intervention towards effective and sustain-
able malaria control in the country [10]. The evidence pre-
sented in such a brief document was exactly the same as it
appeared in the technical research report by Abdulla et al
[6] warning of the increase of resistance to chloroquine.
On that ground, it was recommended that SP should be
adopted as the first-line drug in the interim period, while
efforts to find the most suitable alternative were
underway. It was recommended that the decision to
change the policy should be interim because of the
increasing evidence on high SP resistance in various parts
such as Muheza and Kilombero districts [7]. By that time,
neighbouring countries like Malawi and Kenya, as well as
South Africa and Botswana had already switched to SP as
their first-line drug in 1992 and 1996 respectively [4,24],
while records on SP resistance in Malawi indicating to
have had remained below 10% over the past six years [6].
Multi-centre collaborative study on cost-effectiveness of 
CQ, SP and AQ
In the same year 1999, shortly before the Task Force pre-
sented a summary policy brief paper, a consultancy con-
tract was commissioned by the NMCP and WHO-AFRO to
NIMR, IHRDC and LSHTM to undertake a systematic cost-
effectiveness analysis of alternative antimalarial drugs (SP,
CQ and AQ) and to cost the policy change to an alterna-
tive regimen, and finally to inform the NMCP, the
research community and national policy-makers. The
study projected that within the next 10-year-period, the
cost of transforming the new treatment policy from CQ to
SP as first-line, would be half that of maintaining CQ as
the first-line because the decreasing effectiveness of CQ
led to recurring episodes and repeated treatment of
patients. It was furthermore revealed that within the said
Table 2: Factors facilitating and those hindering the production, dissemination and utilisation of research evidence to guide policy 
formulation process
Factor Barrier Factors Facilitating Factors
Contextual -Poverty: (i) Possibility that the drug proposed to replace the 
existing one may not be cost-effective given the poverty 
situation facing the majority of the residents (ii) Resource 
poor government – meagre health budget, high national debt 
crisis
-UN agencies e.g. WHO and bilateral agencies e.g. DFID, 
SDC, USAID, DANIDA etc. readiness to assist technically 
and financially
-Other countries in the Region also changing their national 
treatment policy
Actors/Institutional -Fear by drug manufacturers and traders mainly when they 
still have huge stocks of the drug proposed to be replaced
-Perceptions by doctors/clinicians based on their experiences 
with prescription/use of alternative antimalarial drugs
-Perceptions of some biomedical researchers and national 
level policy decision makers
Sometimes contrasting/overlapping research evidence about 
drug resistance and cure rates of various drugs (lack of/
delayed consensus)
-Anticipated repercussions about (i) drug's side effects (ii) 
poor compliance by drug users and sometimes by drug 
administrators
-Sustainability in government health budget should donors 
pull out/terminate assistance or when external assistance is 
not guaranteed
-Involvement of key stakeholders in research
-Formation and operation of credible Regional organizations 
such as EANMAT
-Presence formal interface between researchers and policy-
makers i.e. institutional and policy frameworks such as 
TANHERF and professional associations such as national 
Drug Task Policy Force, MAT, TPHA, and NMAC
-Strong local and biomedical research capacity supported by 
Northern Institutions, bilateral organisations such as 
DANIDA, DFID, SDC, USAID and multilateral agencies such 
as TDR
Content -Cost of alternative drugs
-Cost of implementing national policy change
-Some studies carried out on too small scale in terms of 
population sample size and area coverage to justify 
representation of the national picture
-Delay in reporting/disseminating research evidence
-Delay in policy-makers to make informed decisions based on 
research evidence and recommendations
-Poor communication of research evidence: some reports 
being too long, some being too technically/professionally 
written
-Availability of local research evidence on drug resistance
-Detailed research reports (i) e.g. Abdulla et al. [1] on cost-
effectiveness analysis of alternative treatment policy options 
and Research synthesis (ii) e.g. brief reports to feedback 
policy-makersPage 8 of 13
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around US $0.46 per operational failure averted, or US
$33 per death averted, considering changes in outpatient
drug cost only. The study further concluded that the cost
of adopting AQ would be marginally lower than that of
using SP, but due to increasing incidences of side-effects,
AQ should be reserved as the second-line, therefore, rec-
ommending that SP be introduced as an interim first-line
drug anticipating that within the next 10-year period a
better drug would be identified [6,25].
TANHERF
Launched in 1999 through consultative strategy facilitated
by the Commission For Health Research and Develop-
ment (COHRED), the Tanzania National Health Research
Forum (TANHERF) is composed of partner institutions in
health research and their representatives (see Figure 1)
and is an inclusive body whose mission is to ensures that
each partner has clear defined role, is considered as an
asset and shares in the ownership of the mechanism. Its
main function is to ensure that evidence based informa-
tion is correctly utilized by policy-makers and health
managers in order to facilitate the provision of better
health services to populations. Working more closely with
the NIMR where its Secretariat is based, TANHERF is a
consultative body to policy and decision-makers defining
health research priorities and research undertakings, coor-
dination, collaboration, dissemination of findings and
utilization of research results into policy-oriented deci-
sion-making. TANHERF receives and approves reports
from the Essential National Health Research
Coordinating Committee and the National Health
Research Ethics Committee and is a custodian for the dis-
semination of all the national health research results and
through its collaborating institutions, it supports health
research publications including research on drug resist-
ance and antimalarial treatment options [28]. As some of
its members are also members of the previously men-
tioned drug task force and the NMAC, TANHERF has
influenced indirectly the policy change process.
Consensus building
Researchers and members of the Task Force recognized
that numerous and sometimes conflicting evidence had
been presented by researchers through technical research
reports and/or presentations at scientific conferences and
publications in peer reviewed journals. The issue of how
to reconcile the evidence and deliver a common, simple
and clear message to policy-makers was raised. The solu-
tion proposed was to organize stakeholder workshops to
identify, discuss and synthesize the most pertinent
research and health facility-based information concerning
malaria treatment and the way forward. The NMCP in liai-
son with the NMAC, national Drug Policy Task Force and
WHO Country office organized malaria workshops and
meetings with departmental heads and directors within
the MoH and other partner institutions such as the phar-
maceutical industry, bednet manufacturing industries,
research institutions such as NIMR, IHRDC and academic
institutions such as the MUCHS, St. Augustine University
Teaching Hospital – Bugando and KCMC, and interven-
tion projects such as Tanzania Essential Health Interven-
tions Project (TEHIP) and the Adult Morbidity and
Mortality Project (AMMP). One of the latest workshops
held was the one of May 1999 in Bagamoyo in Tanzania
supported by the WHO Roll Back Malaria (RBM) Pro-
gramme. Based on the presentations made by several par-
ticipants during the workshops, the discussion focused on
developing a common way of understanding the trend of
drug resistance and the pros and cons of whether to main-
tain the status quo with CQ as the first-line drug or to
switch to alternative drugs like SP, AQ, chlorproguanil-
dapsone (Lapdap) or others.
Despite the intense discussion about alternative drug reg-
imens, there was a common appreciation that CQ treat-
ment failure rates at different levels and in different drug
monitoring sentinel sites were alarming enough to justify
the need for change. The remaining question that was left
for Parliament to answer in liaison with the MoH and
other partners (e.g. NMCP, NMAC, Drug Policy Task
Force) was whether to replace CQ either with SP as a sin-
gle first-line therapy or in combination with other regi-
mens. RBM, through its representative in East Africa,
expressed readiness to support technically and materially
where necessary and feasible to facilitate any government
policy change decision. As one of the respondents argued,
this was a very important message to the country policy-
makers because of the budget implications of such a
change.
The actual policy change process and current perceptions 
of the change
After the national Task Force on antimalarial drug policy
had presented its policy brief, a series of newspapers and
some private radio stations began to inform the public
that CQ was no longer a recommended drug for malaria
treatment and that the Government was considering
replacing it with a new drug. This information caused
public concern and debates erupted in different parts of
the country about the rationality for the change. Those
involved were the general public, the research commu-
nity, traders, the pharmaceutical industry, and health-care
providers in the public and private health facilities. To
maintain public confidence, the Minister of Health gave
out a press release that indicated the Government stand
concerning the treatment guidelines to be followed while
strategies were underway to make an appropriate deci-
sion. Nobody was assured of the time of the actual policy
change and which type of new treatment guideline wouldPage 9 of 13
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while interviewed in this study:
"It was not clear when the policy would have changed, as
sometimes information that was coming out in the press
releases last year was controversial. There is a time when
the Minister for Health seemed to criticize the informa-
tion that came out in one of the local newspapers that CQ
was no longer effective, and advised the public to remain
patient until his ministry gets sufficient evidence. On the
other hand, researchers continued to disseminate infor-
mation indicating high levels of resistance and suggesting
for finding out a more suitable drug".
Also, according to several respondents, the policy change
was not in the interests of the pharmaceutical manufactur-
ers and traders, who had built up large stocks of CQ and
had profited much from its familiarity among most of
their client populations. Drug supply companies had
already invested in small vans to deliver CQ with a banner
'CHLOROQUINE' on their sides.
Medical practitioners and biomedical researchers consid-
ered it was too early to change the policy. One of the rea-
sons stated was that many people still believed that CQ
was effective despite variations between different areas
and that SP resistance was reported to be on the increase.
Some high-ranking government officers at parliamentary
and ministerial levels identified themselves as being
among those who were still using CQ effectively. Detrac-
tors also relied on a few incidences of patients who had
had side effects with other antimalarial drugs and also
pointed paucity of information available regarding SP
resistance. This fact is similar to one found in the report by
Abdulla et al [6] warning that:
"Anecdotal evidence indicates that many health profes-
sionals are unaware of the extent of resistance to CQ and
do not perceive an urgent need for change".
It was also expressed that the decision to change the policy
was a very sensitive issue considering the financial impli-
cations of the change, both to the government and to the
users of the drugs on one hand, and the lack of expertise
to manage the change and the uncertainty of treatment
outcomes in the use of the new drug.
The Government's official announcement of the policy
change came out of the media in 2000, although the
actual implementation officially started on 1st August
2001. Before this Government policy-decision was
passed, approval by the national parliament was sought
through the speech by the Minister of Health by then to
the Parliament while presenting his ministry's annual
budget [6]. Scientific facts played a prominent role, as the
Minister pointed out that based on the routine health
facility-based morbidity and mortality statistics on
malaria and biomedical research evidence, the MoH was
convinced that it was high time for the government to
replace CQ with a more cost-effective first-line drug that
obviously could alter the existing treatment regimen as a
whole. The agenda for change was presented based on a
summary report by the mentioned Drug Policy Task
Force, supplemented by collective information from
HMIS records submitted to the MoH, drawn from all
regions and policy-research related workshop/conference
proceedings, describing the malaria situation.
A similar speech was the one presented by the new Minis-
ter of Health, this time Hon. Anna Abdallah during the
2002–2003 Budget Session for her ministry [27] in 2002.
With these two speeches, the members of the Parliament
(MPs) were convinced of the need for change, albeit the
decision to switch would be interim, given that more clin-
ical and cost-effectiveness studies were ongoing in some
sentinel sites to establish more evidence regarding the
most appropriate treatment option. This was justified by
the presence of the 5-year Interdisciplinary Monitoring
Programme for Antimalarial Drugs in Tanzania (IMPACT-
Tz) whose initiation involved the MoH as a key stake-
holder. The IMPACT-Tz project is a collaborative venture
between the U.S Centres for Disease Control (CDC),
IHRDC, NIMR, LSHTM, AMMP, TEHIP, MUCHS, WHO
and district health authorities [27,30].
All the respondents in this study expressed the need for
continued research on alternative drug regimens that are
cost-effective if used in real situations, and to publish sys-
tematically organized policy-briefs to keep policy-makers
and national programme managers informed of the
malaria treatment situation and its socio-economic
consequences. It was clarified that each research project
should consider the presentation of concise policy feed-
back report by arranging to meet directly, where possible,
with policy-makers and programme managers to present
their findings and recommendations and share discus-
sions with them whereby various questions can be
answered on the spot and reaching agreement on the way
forward. It was emphasised that the policy reports should
be in the simplest possible language rather than using too
technical scientific jargons which would discourage most
of the non-technical scientific readers among whom are
some policy-makers, planners and programme managers.
Discussion
Factors for the delaying or speeding up of policy change 
process
As this case study shows (Table 2), the process of research-
to-policy change is not simple, it is lengthy and tortuous,
facing numerous challenges from the initiation of thePage 10 of 13
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other key stakeholders to be convinced. Thus, research
intended to build consensus with policy-makers based on
the evidence it has produced would be successful depend-
ing on the following:
(i) research evidence communicated clearly and timely to
policy-decision makers. It needs to be communicated in a
language which can convey the message to policy-making
bodies, as many cannot understand biomedical technical
jargon: research reports that are too technical and too long
face the risk of being discarded by the audience, who are
non-professional in the field or who have limited time to
read/listen the whole report due to their other official
commitments or personal responsibilities;
(ii) consistence of the evidence produced from different
studies on the same research topic/theme: as research evi-
dence from different studies may be more or less overlap-
ping or contradicting each other, policy-makers find it
difficult to make explicit policy change decisions;
(iii) the scale of the study on which recommendations for
policy change are based: policy-makers would be inter-
ested in research evidence drawn from a wide range of
study populations and evidence drawn from different
country sentinel sites are more likely to be acceptable the
purpose of a nationwide policy change. Sometimes, evi-
dence from multi-country studies within the region are
preferred to small scale studies undertaken in one or
several areas in the country. As is evident from the present
case-study, EANMAT reports have contributed substan-
tially to convince the Tanzanian policymakers as has been
the case with the rest of East African NMCPs;
(iv) the anticipated repercussions of making a policy
change decision: such a decision cannot be made in isola-
tion of the standpoint of view of the key stakeholders,
especially drug manufacturers and drug traders, as these
may need to be given an assurance on issues such as stocks
of drug materials or circulation, which have an implica-
tion on the profit and loss accounts of their firms;
(v) policy-makers sometimes lack confidence about the
reported efficacy and safety of the recommended drugs
and may use a few speculative media reports and person-
ally observed treatment outcomes to justify their reasons
for delaying a policy change. As Ralston [31] has
remarked, research and its synthesis and discussion
helped allay the fear of uncertainty and supported action
in the face of marked opposition;
(vi) more often, the government making decisions after
learning from what other countries especially the neigh-
bouring ones have done or are considering doing: If other
countries have not yet changed or are considering a
change to their national drug policies in a way which is
different from the researchers recommendations within
the country, policy decision may take longer time to
change than expected by the local evidence producers/
researchers;
(vi) the production of research evidence is costly: besides
the budget required for the research itself and its dissemi-
nation, the cost of implementing a nationwide policy
change (e.g. production of new guidelines, training of
health workers, supply of newly recommended drug to all
health service delivery levels, replacement of the stocks of
the previously recommended drug, advertisement/public-
ity of the new treatment guidelines through the media,
etc.) is expensive to the provider's e.g. government's side,
besides potential cost associated with health care seeking
and drug utilisation by the target members of the public.
Unless policy-makers are convinced to reason without
doubt about how these potential constraints would be
minimised or avoided, no wonder that it will take time for
the recommended new treatment policy to be approved.
Potential challenges to the next drug combination therapy 
change
In response to recommendation by WHO to countries fac-
ing classical antimalarials to implement artemisin-deriva-
tives-based combination therapy [32], the Tanzanian
Government through the MoH has already explicitly
announced its strategy for replacing SP monotherapy with
artemisinin-based combination therapy (ACT) with effect
from 2006 [33]. Such a policy move faces similar chal-
lenges such as reservations/inadequate faith by the
research and drug prescribing community who anticipate
immediate parasite resistance to ACT mainly due to the
majority poor residents potential failure to comply with
the treatment schedules because of the drug cost, individ-
ual tastes and preferences driven by their perceptions of
the drug with the sulpha component and availability of
alternative drugs in the liberal retail market (as some peo-
ple may prefer monotherapy such as AQ or other drugs).
The concern about cost related barriers both to the provi-
sion and utilisation of artemisinin drug combination
therapy related services have been documented by other
authors [2,34-37]. There is also failure of the drug users to
take the full course/dose of the recommended drug as
some of them may prefer the drug taken once and for all
rather than the one whose dose has to be completed by
taking it several times. Another failure may be on the side
of some health practitioners to administer the drug as rec-
ommended in the policy guidelines due to lack of training
on the administration of the new drug or other motives
driving their practices e.g. private-for-profit health care
drug administrators may be driven by the preferences of
alternative types of drugs by their clients or may prescribePage 11 of 13
(page number not for citation purposes)
Malaria Journal 2005, 4:51 http://www.malariajournal.com/content/4/1/51alternative drugs which they access easily and cheaply in
the market and which apparently are more profitable.
Conclusions and recommendations
Despite taking longer than expected, the eventual decision
by the Tanzanian government to revise its malaria treat-
ment policy in 2000 and to enforce its effective imple-
mentation in 2001 marks the explicit policy decision
output backed up with research evidence. Also, the com-
mitment by the MoH to support clinical trials e.g. the
IMPACT-Tz study and the one by Abdulla et al., can be
seen as intermediate explicit policy decision points. The
present case study shows that the road towards changing
a nationwide drug policy is long and multifaceted. How-
ever, the ultimate decision to change the national policy
depends also on evidence backed by demand-driven sys-
tematic research. As research plays a role in modifying
political, technical and social values, the following is sug-
gested: (a) need to involve key stakeholders at all stages of
research to ensure it is always demand-driven (b) need to
consider how and when research information should be
communicated to or between different stakeholders (e.g.
inviting policy-makers and the media in policy-brief
workshops/meetings), as sometimes done by EANMAT,
TEHIP, NIMR, COSTECH and other institutions/organi-
zations involved in the research-to-policy partnership. As
stated by Eisenberg [38], EANMAT contributed to glo-
balize the evidence and localize the decisions, thus help-
ing to obtain support for change (c) the imperativeness of
appreciating that is unusual for all policy-makers are able
to interpret research findings presented in too technical
language, so a simplified version of the biomedical lan-
guage is crucial for the optimal utilisation of the evidence
presented (d) need for continued support to build capac-
ity both in research, evidence presentation and in policy
analysis in developing health systems (e) The importance
of multi-country evidence on drug resistance to influence
national policy change decision is mostly inescapable
especially in countries located in the same region (e.g.
EANMAT or WENMAT countries] as part of globalization,
albeit it is up to the individual countries to find out the
feasibility of whatever policy change decision move in the
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